Appln No. 10/680,818 Amdt date March 26, 2007 Reply to Office action of September 26, 2006

Amendments to the Specification:

On page 3, line 19, please amend the paragraph to read as follows:

"The present invention provides methods for labeling structures, including .beta.-amyloid plaques and neurofibrillary tangles, in vivo and in vitro, and comprises contacting a compound of formula (I):

with mammalian tissue. In formula (I), R_1 is selected from the group consisting of --C(O)-alkyl, --C(O)-alkylenyl- R_4 , --C(O)O-alkylenyl R_4 , --C=C(CN).sub.2-alkyl, --C=C(CN)2-alkylenyl- R_4 ,

$$R_6$$
 R_8
 R_8

 R_4 is a radical selected from the group consisting of alkyl, substituted alkyl, aryl and substituted aryl; R_5 is a radical selected from the group consisting of --NH2, --OH, --SH, --NH-alkyl, --NH-alkylenyl- R_4 , --O-alkylenyl- R_4 , --S-alkyl, and --S-alkylenyl- R_4 ; $R_{.6}$ is a radical selected from the group consisting of --CN, --COOH, --C(O)O-alkyl, --C(O)O-alkylenyl- R_4 , --C(O)-alkyl, --C(O)-alkylenyl- $R_{.4}$, --C(O)-halogen, --C(O)NH-alkyl, --C(O)NH-alkylenyl- R_4 ; R_7 is a radical selected from the group consisting of O, NH, and S; and R_8 is N_7 O or S_7 R_8 is N_7 .

On page 4, line 18, please amend the paragraph to read as follows:

" In still another embodiment, the invention is directed to a composition comprising a compound of formula (I):

-2-

Appln No. 10/680,818
Amdt date March 26, 2007
Reply to Office action of September 26, 2006

 R_1 is selected from the group consisting of --C(O)-alkyl, --C(O)-alkylenyl- R_4 , --C(O)O-alkyl, --C(O)O-alkylenyl- R_4 --C.=C(CN).sub.2-alkyl, --C=C(CN)₂-alkylenyl- R_4 ,

$$R_6$$
 R_6 R_6 R_6 R_6 R_7 R_7

 R_4 is a radical selected from the group consisting of alkyl, substituted alkyl, aryl and substituted aryl; R_5 is a radical selected from the group consisting of --NH₂, --OH, --SH, --NH-alkyl, --NH-alkylenyl- R_4 , --O-alkylenyl- R_4 , --S-alkyl, and --S-alkylenyl- R_4 R_6 is a radical selected from the group consisting of --CN, --COOH, --C(O)O-alkyl, --C(O)O-alkylenyl- R_4 , --C(O)-alkylenyl- R_4 , --C(O)-halogen, --C(O)NH₂ --C(O)NH-alkyl, --C(O)NH-alkylenyl- R_4 ; R_7 is a radical selected from the group consisting of O, NH, and S; R_8 is N, O or S; R_8 is N; R_2 is selected from the group consisting of alkyl and alkylenyl- R_5 and R_3 is alkylenyl- R_5 , and R_5 is selected from the group consisting of --OH, --OTs, halogen, spiperone, spiperone ketal, and spiperone-3-yl, or R_2 and R_3 together form a heterocyclic ring, optionally substituted with at least one radical selected from the group consisting of alkyl, alkoxy, OH, OTs, halogen, alkylenyl- R_5 carbonyl, spiperone, spiperone ketal and spiperone-3-yl. One or more of the hydrogen, halogen or carbon atoms can optionally be replaced with a radiolabel.

On page 7, line 16, please replace the second pictured chemical structure with the following corrected chemical structure:

On page 8, line 10, please amend the paragraph to read as follows:

-3-

Appln No. 10/680,818 Amdt date March 26, 2007 Reply to Office action of September 26, 2006

"The present invention is directed to methods for labeling structures such as $.\beta$ -amyloid plaques and neurofibrillary tangles in vivo and in vitro. The methods all involve contacting a compound of formula (I):

with mammalian tissue. In formula (I), R_1 is selected from the group consisting of --C(O)-alkyl, --C(O)-alkylenyl- R_4 --C=C(CN)₂-alkyl, --C=C(CN)₂-alkylenyl- R_4 ,

$$R_6$$
 N and R_8 N R_7

 R_4 is a radical selected from the group consisting of alkyl, substituted alkyl, aryl and substituted aryl. R_5 is a radical selected from the group consisting of --NH₂, --OH, --SH, --NH-alkyl, --NH-alkylenyl- R_4 , --O-alkylenyl- R_4 , --S-alkyl, and --S-alkylenyl- R_4 . R. sub.6 is a radical selected from the group consisting of --CN, --COOH, --C(O)O-alkyl, --C(O)O-alkylenyl- R_4 , --C(O)-alkylenyl- R_4 , --C(O)-halogen, --C(O)NH-alkyl, --C(O)NH-alkylenyl- R_4 . R_7 is a radical selected from the group consisting of O, NH, and S. R_8 is N.

-4-